Full Press Release Details
FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT
THIS SUPPORT AGREEMENT (this "Agreement"),
dated as of March [ ], 2024, is made by and among BiomX Inc., a Delaware corporation ("Parent"), Adaptive Phage
Therapeutics, Inc., a Delaware corporation (the "Company"), and the undersigned holder ("Stockholder")
of shares of capital stock (the "Shares") of Parent.
WHEREAS, Parent, BTX Merger Sub I, Inc.,
a Delaware corporation and a direct wholly owned subsidiary of Parent ("First Merger Sub"), BTX Merger Sub II,
LLC, a Delaware limited liability company and a direct wholly owned subsidiary of Parent ("Second Merger Sub"),
and the Company, have entered into an Agreement and Plan of Merger, dated of even date herewith (the "Merger Agreement"),
providing for the merger of First Merger Sub with and into the Company (the "First Merger") and the merger of
the Company with and into Second Merger Sub (the "Second Merger" and, together with the First Merger, the "Merger");
WHEREAS, Stockholder beneficially owns
and has sole or shared voting power with respect to the number of Shares, and those certain warrants to purchase shares of Parent Common
Stock with an exercise price of $0.001 per Parent Common Stock ("Parent Pre-Funded Warrants"), in each case
in the number of Shares indicated opposite Stockholder's name on Schedule 1 attached hereto;
WHEREAS, as an inducement and a condition
to the willingness of Parent, First Merger Sub, Second Merger Sub and the Company to enter into the Merger Agreement, and in consideration
of the substantial expenses incurred and to be incurred by them in connection therewith, Stockholder has agreed to enter into and perform
WHEREAS, all capitalized terms used in
this Agreement without definition herein shall have the meanings ascribed to them in the Merger Agreement.
NOW, THEREFORE, in consideration of, and
as a condition to, Parent, First Merger Sub, Second Merger Sub and the Company's entering into the Merger Agreement and proceeding
with the transactions contemplated thereby, and in consideration of the substantial expenses incurred and to be incurred by them in connection
therewith, Stockholder, Parent and the Company agree as follows:
[Remainder of Page has Intentionally Been Left
EXECUTED as of the date first above written.
| [STOCKHOLDER] | ||
| Signature: | ||
| Name (if an Entity): | ||
| Title (if an Entity): |
[Signature Page to Support Agreement]
EXECUTED as of the date first above written.
| BIOMX INC. | ||
| By: | ||
| Name: | ||
| Title: |
[Signature Page to Support Agreement]
EXECUTED as of the date first above written.
| Adaptive Phage Therapeutics, Inc. | ||
| By: | ||
| Name: | ||
| Title: |
[Signature Page to Support Agreement]